Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.
Under the new option, patients would pay less than the cash price for Eli Lilly & Co.’s Zepbound or Novo Nordisk A/S’s Wegovy, but typically more than the normal copay. Meanwhile, health plans would spend less on the weight loss drugs than under the standard structure, an incentive to get more employers to cover them.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.